RCKT is trading about 5% up now at $3.70, continuing a steady rebound from late June lows. Recent coverage focuses on its longer-term upside potential and mixed-but-optimistic analyst sentiment rather than any fresh catalyst. With no new earnings, FDA, or deal news emerging today, the move appears aligned with a generally positive market backdrop and investors re-rating beaten-down biotech names.